torcetrapib has been researched along with niacin in 13 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (niacin) | Trials (niacin) | Recent Studies (post-2010) (niacin) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 11,974 | 462 | 1,488 |
| Protein | Taxonomy | torcetrapib (IC50) | niacin (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 0.14 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.14 | |
| Hydroxycarboxylic acid receptor 2 | Homo sapiens (human) | 0.1726 | |
| Hydroxycarboxylic acid receptor 2 | Mus musculus (house mouse) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansell, BJ | 1 |
| Bloomgarden, ZT | 1 |
| Suckling, K | 1 |
| Tan, KC | 1 |
| Rosenson, RS | 1 |
| Rizzoni, D; Rossi, GP | 1 |
| Schaefer, JR | 1 |
| Kaski, JC | 1 |
| Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F | 1 |
| Taylor, J | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
| McCullough, PA; Shin, HJ | 1 |
6 review(s) available for torcetrapib and niacin
| Article | Year |
|---|---|
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines | 2005 |
Reverse cholesterol transport in type 2 diabetes mellitus.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Biological Transport; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Liver; Liver X Receptors; Mice; Niacin; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Quinolines; Rabbits; Scavenger Receptors, Class B; Thiazolidinediones | 2009 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia | 2014 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People | 2014 |
7 other study(ies) available for torcetrapib and niacin
| Article | Year |
|---|---|
2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Quinolines; Simvastatin; Triglycerides | 2005 |
Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
Topics: Cholesterol, HDL; Flushing; Humans; Hypolipidemic Agents; Niacin; Quinolines; Treatment Failure | 2007 |
The continuing complexities of high-density lipoprotein metabolism in drug discovery and development.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Drug Design; Humans; Lipoproteins, HDL; Niacin; Quinolines | 2007 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2010 |
Therapy: raising HDL cholesterol levels: a flight of Icarus?
Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines | 2010 |
HDL- cholesterol: a nut too hard to crack?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Niacin; Quinolines | 2012 |
CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
Topics: Amides; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; Quinolines; Sulfhydryl Compounds | 2013 |